Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ferumoxides
- Development stage
- Unknown
- Lead developer
- Azurity Pharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ferumoxides is a superparamagnetic iron oxide (SPIO) contrast agent used in magnetic resonance imaging (MRI) primarily for the detection and evaluation of liver lesions. Developed by Advanced Magnetics, it consists of non-stoichiometric magnetite crystals coated with dextran. Upon intravenous administration, the particles are selectively taken up by the phagocytic Kupffer cells of the reticuloendothelial system (RES) in healthy liver and spleen tissue. The superparamagnetic nature of the iron oxide particles significantly shortens the transverse relaxation time (T2), resulting in a marked decrease in signal intensity (darkening) of normal parenchyma on T2-weighted images. Because most malignant tumors (such as metastases or hepatocellular carcinoma) lack functional Kupffer cells, they do not sequester the agent and appear relatively hyperintense against the darkened background of normal liver tissue, thereby enhancing lesion detectability and characterization.
- Brand names
- FeridexEndoremFeridex I.V.
- Other names
- FerumoxideSuperparamagnetic iron oxideSPIO
02
Targets
MSR1 (Amyloid beta precursor protein binding family B member 3)
Beyond the preview
Go deeper on ferumoxides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ferumoxides.